Clinical Trial Update: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC [Phase 2]

View source ↗

Summary

Reports a Phase 2 clinical trial evaluating Fulzerasib sequential with Sintilimab and platinum-doublet chemotherapy as neoadjuvant therapy for resectable KRAS G…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fulzerasib (IBI351)
• Sintilimab (sintilimab)

Snippet

Sponsor: Jianxing He | Conditions: Resectable NSCLC, KRAS G12C Mutation | Phase 2 | Status: RECRUITING